Progenics Pharma Q1 revenues up
The company has reported a net loss of $22.93m, or $0.69 loss per diluted share, compared to net loss of $18.58m or $0.58 loss per diluted share, for
Biologics contract development and manufacturing organisation (CDMO) AsymBio is set to secure 1.2397bn yuan (approximately $184m) from Asymchem Group, Hillhouse Qirui and other investors to support its long-term growth.